Corpus ID: 228083453

What Were They Thinking? Pharmacologic priors implicit in a choice of 3+3 dose-escalation design

  title={What Were They Thinking? Pharmacologic priors implicit in a choice of 3+3 dose-escalation design},
  author={David C Norris},
  journal={arXiv: Methodology},
  • David C Norris
  • Published 2020
  • Mathematics, Biology, Psychology
  • arXiv: Methodology
If explicit, formal consideration of clinical pharmacology at all informs the design and conduct of modern oncology dose-finding trials, the designs themselves hardly attest to this. Yet in conducting a trial, investigators affirm that they hold reasonable expectations of participant safety - expectations that necessarily depend on beliefs about how certain pharmacologic parameters are distributed in the study population. Thus, these beliefs are implicit in a trial's presumed conformance to a… Expand

Figures and Tables from this paper


Retrospective analysis of a fatal dose-finding trial
A Bayesian dose-response model for a single ordinal toxicity of bispecific T cell engager AFM11 is developed, and it is demonstrated the incompatibility of that design with any reasonable expectation of safety. Expand
Model-Based Dose Escalation Designs in R with crmPack
The R package crmPack provides a simple and unified object-oriented framework for model-based dose escalation designs that enables the standard use of such designs, while being able to flexibly adapt and extend them. Expand
One-size-fits-all dosing in oncology wastes money, innovation and lives.
The principle of Dose Titration Algorithm Tuning (DTAT) offers a reasoned strategy for accomplishing individualize drug dosing and is presented to investors in pharmaceutical innovation who are willing to develop and field innovative Phase 1 trial methodologies that solve this problem. Expand
Dose Transition Pathways: The Missing Link Between Complex Dose-Finding Designs and Simple Decision-Making
DTP removes the fears of model-based designs as unknown, complex systems and can serve as a handbook, guiding decision-making for each dose update, in an acute myeloid leukemia trial. Expand
Dose-finding clinical trial design for ordinal toxicity grades using the continuation ratio model: an extension of the continual reassessment method
While the ordinal designs did not perform significantly better than the binary counterpart, they were able to incorporate maximal toxicity information available into a feasible dose-finding design without compromising overall design performance. Expand
The determination and interpretation of the therapeutic index in drug development
This article critically discusses the various aspects of TI determination and interpretation in drug development for both small molecule drugs and biotherapeutics. Expand
Shortening the timeline of pediatric phase I trials: the rolling six design.
The rolling six design may significantly decrease the duration of pediatric phase I studies without increasing the risk of toxicity. Expand
Dose-Finding Based on Multiple Toxicities in a Soft Tissue Sarcoma Trial
A Bayesian method for dose-finding in the sarcoma trial based on a vector of correlated, ordinal-valued toxicities with severity levels varying with dose, which has worked in the trial and is provided for general application. Expand
A comparison of two phase I trial designs.
The results indicate that with the continual reassessment method, more patients will be treated at very high doses and the trials will take longer to complete. Expand
The intellectual health of clinical drug evaluation
  • L. Sheiner
  • Medicine
  • Clinical pharmacology and therapeutics
  • 1991
It is necessary to select patients suitable for vaginal or laparoscopic mesh placement on the basis of prior history and once they provide informed consent for surgery, the likelihood of adverse events and their prognosis is low. Expand